Abstract: In today’s rapidly evolving cyber landscape, the growing sophistication of attacks, including the rise of zero-day exploits, poses critical challenges for network intrusion detection.
About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...
The firm at the JP Morgan Healthcare Conference additionally expects a regulatory decision on its gene therapy RGX-121 for Hunter syndrome next month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback